Literature DB >> 21847318

Motor fluctuations and dyskinesias (diagnosis and management).

.   

Abstract

Entities:  

Year:  2011        PMID: 21847318      PMCID: PMC3152175     

Source DB:  PubMed          Journal:  Ann Indian Acad Neurol        ISSN: 0972-2327            Impact factor:   1.383


× No keyword cloud information.
Motor complications appear in approximately 50% of patients on levodopa (LD) therapy for more than 5 years. Chase et al[1] reported that 28--84% of LD-treated patients develop motor fluctuations after an average of 4.1 years after starting LD therapy. These occur as a result of progression of the disease process (increased neuronal degeneration) and the cumulative effect of prolonged treatment with dopaminergic drugs, especially LD.

The Motor Complications include

Motor fluctuations Wearing off effects (end-of-dose deterioration): This is the most common initial manifestation of motor fluctuation. The patient starts to feel the reappearance of motor symptoms before the next dose. It is predictable and occurs 2--4 h after a dose of LD.[2] In the initial stages, the symptoms great promptly alleviated after the same dose of dopaminergic medications. However, later the dose needs to be increased or another medicine for PD needs to be added. “ON” and “OFF” phenomena which can be predictable or unpredictable: Gradually, the patient starts having “OFF” periods when not on medications or after the effect of medicine goes away, and a predictably good “ON” response about 45 min to an hour after intake of LD (or other dopaminomimetics). However, as the disease progress, the “ON” response may be suboptimal or erratic, and patient can develop unpredictable “ON”--“OFF” motor fluctuations. These “motor shifts” occur as a result of loss of presynaptic dopamine terminals and from fluctuating neurotransmitter level.[1] Nighttime deterioration: In moderate to advanced disease, patients wake up in the night with motor symptoms, difficulty in rolling over in bed, muscular discomfort, and frequent urination. Early morning deterioration: This can often be associated with painful foot dystonia.[3] Dyskinesias/ dystonias. These can be of the following types:[34] At peak-dose, more often dyskinesias During “OFF” periods, more often dystonias A combination of peak-dose and “OFF” period (biphasic), patients often cycling in these two phases

Diagnosis

Diagnosis is based on meticulous history from the patient and caregivers. Patients need prolonged observation before and after a dose of medications for PD. Patients are often not concerned about the minor dyskinesias and therefore may deny this symptom. However, the caregivers are in a better position to confirm the presence of dyskinesias. When in doubt about the presence or degree of motor complications, patients should be given 24 h diaries to be completed at home, marking the OFF, ON stages, time and severity of dyskinesias, and temporal relationship with the medications. If necessary, patients and caregivers should be shown video clippings of patients with dyskinesias. Finally, patients may need a short admission in the hospital and evaluated in OFF and ON stages with UPDRS scales and scales for dyskinesias.

Principles of Management

Suboptimal clinical response, wearing-off phenomenon, delayed “ON” or no “ON” without dyskinesias or minimal dyskinesias Optimize the current dosage of anti-PD medications (increase the strength of each dose or give more frequently) without causing side effects. If already on optimal dosage of levodopa-carbidopa (LD) preparation only, try adding COMT-inhibitor-entacapone (200 mg with each dose of LD, up to 1600 mg/day,[56] changing over to controlled-release (CR) preparation of LD or add CR preparation to the standard LD preparation (especially a bedtime dosage of 200/50 mg CR preparation of LD for nighttime wearing-off),[78] adding MAO-B inhibitor, e.g. selegiline (5 mg at morning and afternoon) or rasagiline (0.5 mg at morning, later can be increased to 1.0 mg at morning),[9] adding amantadine, 100 mg once daily, increased to twice a day,[10] adding a dopamine agonist (e.g. ropinirole or pramipexole),[3] If already on an optimal dosage of dopamine agonist only, try switching over to another agonist (e.g. from pramipexole to ropinirole and vice versa) adding LD preparation (immediate or CR preparation) adding MAO-B inhibitor or amantadine redistribute dietary protein consider surgery for PD Nighttime deterioration: The following strategies may be tried: A CR preparation of LD at bedtime An extra dose of standard LD around midnight when patients wakes up Addition of dopamine agonist or entacapone if patient is not on these drugs. Early morning deterioration: Often patients are relieved by a standard preparation of LD, which can be given crushed and with carbonated drink or on empty stomach, if patient can tolerate. Patients with disabling dyskinesias Choreiform dyskinesias Peak dose dyskinesias: The following strategies can be tried: If patient is on CR preparation of LD, switch over to immediate release one[11] Reduce individual dose of LD and give more frequent If patient is on a COMT inhibitor, stop the drug Reduce the total daily dose of LD and add a dopamine agonist (ropinirole or pramipexole) or increase the dose of dopamine agonist if patient is already taking one Reduce dosage of LD and add amantadine. The dose of amantadine need to be 300-400 mg/day and the benefits tend to be short lived[12] Reduce LD and add anticholinergic drugs (e.g. trihexyphenidyl) Remove selegiline or rasagiline Continuous drug delivery such as subcutaneous apomorphine or duodenal LD may be considered[13] Atypical neuroleptics such as clozapine may be of help[14] Consider surgery for PD (deep brain stimulation of bilateral subthalamic nucleus is most preferred target)[3] Biphasic dyskinesias: It is difficult to treat this condition, but the following strategies may be tried.[11] If patient is on a CR preparation of LD, change over to immediate release one Increase the total dose of LD Restrict use of LD to several early and/or mid-day doses Add or increase the dose of dopamine agonist ubcutaneous apomorphine injections can be tried at selected times Try continuous drug delivery (as mentioned above) Assess for psychiatric problems and treat when present Try behavioural management Consider surgery for PD Dystonias Peak-dose dystonia Reduce dose of LD Add or increase dose of dopamine agonists Consider surgery for PD Early-morning / OFF-period dystonia Add CR preparation of LD at bedtime Add dopamine agonist at bedtime Add COMT inhibitor Early morning immediate release LD may be tried 1--2 h before getting up from bed Other drugs such as baclofen, diazepam, or anticholinergic drugs can be tried In focal dystonia, injection of botulinum toxin type A in the dystonic muscles can be tried Unpredictable “ON-OFF” periods: The following options may be considered. Adjust time and dose of LD Add dopamine agonist Add COMT inhibitor Add rasagiline Change to liquid preparation of LD:[15] Daily liquid preparation of LD needs to be prepared by crushing ten tablets of standard (immediate release) 100/25 levodopa/carbidopa, 2 g of ascorbic acid and dissolving in 1 L of water. This solution need to be administered every 60-90 min intervals, the dose being adjusted according to the response and side effects. Redistribute dietary protein Subcutaneous apomorphine Freezing (motor blocks) Only in “OFF” state Management strategies as like in patients with wearing-off Manage anxiety, if present, by appropriate drugs or behavioural therapy and nonpharmacologic techniques that involve the use of sensory or mental imagery, cues, or devices.[1116] Both in “OFF” and “ON” stages Increase LD to make optimal “ON” Sensory cues Assistive devices Manage anxiety, if present, by appropriate drugs or behavioural therapy Only “ON” freezing It is very difficult to manage and patients sometimes benefit by reducing the dose of LD. In summary, medical management of motor fluctuations in PD is challenging. Surgical treatment of PD may be a better option for carefully selected patients.
  15 in total

Review 1.  An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines.

Authors:  C W Olanow; R L Watts; W C Koller
Journal:  Neurology       Date:  2001-06       Impact factor: 9.910

2.  Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.

Authors:  L V Metman; P Del Dotto; K LePoole; S Konitsiotis; J Fang; T N Chase
Journal:  Arch Neurol       Date:  1999-11

3.  Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.

Authors:  J E Ahlskog; M D Muenter; P G McManis; G N Bell; P A Bailey
Journal:  Mayo Clin Proc       Date:  1988-09       Impact factor: 7.616

4.  Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.

Authors:  O Rascol; D J Brooks; E Melamed; W Oertel; W Poewe; F Stocchi; E Tolosa
Journal:  Lancet       Date:  2005 Mar 12-18       Impact factor: 79.321

5.  Evaluation of a modified inverted walking stick as a treatment for parkinsonian freezing episodes.

Authors:  M A Dietz; C G Goetz; G T Stebbins
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

6.  Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group.

Authors: 
Journal:  Ann Neurol       Date:  1997-11       Impact factor: 10.422

7.  Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study.

Authors:  M C Kurth; J W Tetrud; I Irwin; W H Lyness; J W Langston
Journal:  Neurology       Date:  1993-05       Impact factor: 9.910

Review 8.  Treating motor fluctuations with controlled-release levodopa preparations.

Authors:  W C Koller; R Pahwa
Journal:  Neurology       Date:  1994-07       Impact factor: 9.910

Review 9.  How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?

Authors:  Stanley Fahn
Journal:  Ann Neurol       Date:  2008-12       Impact factor: 10.422

Review 10.  New strategies in motor parkinsonism.

Authors:  Angelo Antonini
Journal:  Parkinsonism Relat Disord       Date:  2007       Impact factor: 4.891

View more
  1 in total

1.  Characteristics of advanced Parkinson's disease patients seen in movement disorder clinics - Australian results from the cross-sectional OBSERVE study.

Authors:  Andrew Evans; Victor S C Fung; John D O'Sullivan; Rick Stell; Richard White; David R Williams; Samira Femia; Koray Onuk
Journal:  Clin Park Relat Disord       Date:  2020-10-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.